Trials / Recruiting
RecruitingNCT07204418
A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
A Phase 1, 4-part, Open-label Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal/extensive, intermediate, poor, and ultrarapid metabolizers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xanomeline/ Trospium Chloride | Specified dose on specified days |
Timeline
- Start date
- 2025-10-13
- Primary completion
- 2026-12-03
- Completion
- 2026-12-03
- First posted
- 2025-10-02
- Last updated
- 2026-02-19
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07204418. Inclusion in this directory is not an endorsement.